FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA page documents Bayer's supplemental application for Stivarga (regorafenib), indicating a label change is being sought.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastrointestinal Stromal Tumor
• Hepatocellular Carcinoma

Drugs mentioned

• Stivarga (regorafenib)

Snippet

SUPPL AP for STIVARGA (REGORAFENIB)